Endo Pharma (ENDP) Tops Q4 EPS by 8c; Guides FY12 EPS, Revs

February 24, 2012 7:04 AM EST
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q4 EPS of $1.40, $0.08 better than the analyst estimate of $1.32. Revenue for the quarter came in at $803.4 million versus the consensus estimate of $802.9 million.

Endo Pharmaceuticals Holdings sees FY2012 EPS of $5.00-$5.20, versus the consensus of $5.46. Endo Pharmaceuticals Holdings sees FY2012 revenue of $3.15-$3.30 billion, versus the consensus of $3.23 billion.

For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings